1,386 Shares in Insulet Corporation $PODD Purchased by Financial Advocates Investment Management

Financial Advocates Investment Management acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,386 shares of the medical instruments supplier’s stock, valued at approximately $435,000.

Other large investors also recently bought and sold shares of the company. Evelyn Partners Investment Management Services Ltd increased its holdings in shares of Insulet by 28.7% in the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 39 shares during the last quarter. Sequoia Financial Advisors LLC boosted its holdings in Insulet by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock worth $634,000 after purchasing an additional 45 shares during the period. Nissay Asset Management Corp Japan ADV increased its stake in Insulet by 0.6% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after purchasing an additional 48 shares during the last quarter. Mather Group LLC. raised its holdings in shares of Insulet by 4.4% during the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock worth $360,000 after purchasing an additional 48 shares during the period. Finally, Brooklyn Investment Group raised its holdings in shares of Insulet by 7.0% during the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock worth $209,000 after purchasing an additional 52 shares during the period.

Insiders Place Their Bets

In other Insulet news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on PODD. Wells Fargo & Company lifted their price target on shares of Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Jefferies Financial Group increased their price objective on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Rothschild & Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. BTIG Research upped their target price on Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a report on Friday, November 21st. Finally, UBS Group upgraded Insulet from a “neutral” rating to a “buy” rating and increased their price target for the stock from $355.00 to $400.00 in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $379.65.

Insulet Stock Performance

PODD stock opened at $326.80 on Friday. The company has a 50-day simple moving average of $322.06 and a 200 day simple moving average of $316.28. The company has a market capitalization of $22.99 billion, a P/E ratio of 99.33, a PEG ratio of 2.64 and a beta of 1.39. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same period in the previous year, the firm earned $1.08 EPS. Insulet’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.